Evolocumab reduces cardiovascular events in patients with heart disease, finds studyBMJ 2017; 356 doi: https://doi.org/10.1136/bmj.j1394 (Published 20 March 2017) Cite this as: BMJ 2017;356:j1394
- Susan Mayor
Evolocumab reduced the risk of major cardiovascular events by 15% in patients with atherosclerotic cardiovascular disease who were already taking statins, a study has found.
The study randomised 27 564 patients with clinically evident atherosclerotic cardiovascular disease to evolocumab (either 140 mg every two weeks or 420 mg monthly by subcutaneous injection) or to placebo.1 Study participants had fasting concentrations of low density lipoprotein (LDL) cholesterol of ≥1.8 mmol/L on moderate or high intensity statin therapy, and 81% had a …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial